Entrada Therapeutics (NASDAQ:TRDA) Major Shareholder Bioventures 2014 L.P. Mpm Sells 26,522 Shares

Entrada Therapeutics, Inc. (NASDAQ:TRDA) major shareholder Bioventures 2014 L.P. Mpm sold 26,522 shares of the stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $7.54, for a total transaction of $199,975.88. Following the sale, the insider owned 4,332,917 shares in the company, valued at approximately $32,670,194.18. This trade represents a 0.61% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Bioventures 2014 L.P. Mpm also recently made the following trade(s):

• On Wednesday, August 26th, Bioventures 2014 L.P. Mpm sold 14,569 shares of Entrada Therapeutics stock. The shares were sold at an average price of $7.06, for a total value of $102,857.14.
• On Monday, August 24th, Bioventures 2014 L.P. Mpm sold 21,623 shares of Entrada Therapeutics stock. The stock was sold at an average price of $7.34, for a total value of $158,712.82.

Entrada Therapeutics Trading Down 8.1%

NASDAQ:TRDA opened at $7.00 on Thursday. The company has a 50-day moving average of $7.08 and a 200-day moving average of $9.36. The firm has a market cap of $272.58 million, a price-to-earnings ratio of -1.77 and a beta of -0.26. Entrada Therapeutics, Inc. has a twelve month low of $5.02 and a twelve month high of $16.45.

Entrada Therapeutics (NASDAQ:TRDA) last issued its earnings results on Wednesday, August 5th. The company reported ($1.01) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.04). Entrada Therapeutics had a negative return on equity of 57.61% and a negative net margin of 3,537.73%.The business had revenue of $0.90 million for the quarter, compared to the consensus estimate of $2.32 million. On average, research analysts forecast that Entrada Therapeutics, Inc. will post -4.03 earnings per share for the current year.

Institutional Trading of Entrada Therapeutics

Several institutional investors have recently bought and sold shares of the stock. Geode Capital Management LLC increased its holdings in shares of Entrada Therapeutics by 7.2% during the second quarter. Geode Capital Management LLC now owns 631,554 shares of the company’s stock worth $4,245,000 after buying an additional 42,479 shares in the last quarter. Rhumbline Advisers increased its position in Entrada Therapeutics by 8.3% in the second quarter. Rhumbline Advisers now owns 39,095 shares of the company’s stock worth $263,000 after purchasing an additional 2,982 shares during the period. American Century Companies Inc. increased its position in Entrada Therapeutics by 10.8% in the second quarter. American Century Companies Inc. now owns 75,094 shares of the company’s stock worth $505,000 after purchasing an additional 7,301 shares during the period. Prudential Financial Inc. boosted its stake in shares of Entrada Therapeutics by 23.4% in the 2nd quarter. Prudential Financial Inc. now owns 28,340 shares of the company’s stock valued at $190,000 after purchasing an additional 5,370 shares during the last quarter. Finally, Invesco Ltd. grew its position in shares of Entrada Therapeutics by 34.2% during the 2nd quarter. Invesco Ltd. now owns 22,393 shares of the company’s stock worth $150,000 after buying an additional 5,702 shares during the period. Institutional investors and hedge funds own 86.39% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. Roth Capital reissued a “buy” rating and set a $11.00 price target on shares of Entrada Therapeutics in a research report on Wednesday, August 12th. Weiss Ratings downgraded shares of Entrada Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, August 13th. Guggenheim dropped their price target on shares of Entrada Therapeutics from $20.00 to $17.00 and set a “buy” rating on the stock in a research note on Monday, June 8th. Finally, HC Wainwright cut shares of Entrada Therapeutics from a “buy” rating to a “neutral” rating in a research note on Friday, May 8th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $17.75.

Entrada Therapeutics Company Profile

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.